Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Proxima

Proxima

Proxima develops AI-guided drug discovery software for therapeutics research.

: 11-50
: Company
: 2019
: New York, NY, USUnited States

Proxima is a New York biotechnology company developing an AI-guided drug discovery platform. It combines computational biology and machine learning to support therapeutics research and help guide discovery work from data-driven hypotheses to candidate exploration.

The platform is positioned for teams working in drug discovery and therapeutics R&D that need software-led methods alongside biology. Public sources describe it as a computational approach that fits into research workflows where biological data and modeling are used to inform decisions across early-stage discovery.

Similar Companies

Numerion Labs

numerionlabs.ai

OneThree Biotech

onethree.bio

Superluminal Medicines

superluminalrx.com

Iambic Therapeutics

iambic.ai

Pathos AI

pathos.com

Harmonic Discovery

Seismic Therapeutic

seismictx.com

Unravel Biosciences

unravel.bio

Sinopia Biosciences

sinopiabio.com

Diffuse Bio

diffuse.bio

Biolexis Therapeutics

biolexistx.com

Generate Biomedicines

TandemAI

tandemai.com

Biosim

Boltzmann Labs

boltzmann.co

Pepper Bio

pepper.bio

BioMap

biomap.com

Metaphore Biotechnologies

metaphorebio.com

Avicenna Biosciences

avicenna-bio.com

Phronesis Artificial Intelligence

phronesisai.com

Quick Facts

Who are Proxima's competitors?

Companies similar to Proxima include Numerion Labs, OneThree Biotech, Superluminal Medicines and Iambic Therapeutics.

When was Proxima founded?

Proxima was founded in 2019.

Where is Proxima's headquarters located?

Proxima's headquarters is located in New York, NY, US.

When was Proxima's last funding round?

Proxima's most recent funding round was for $80M (USD) in January 2026.

How much disclosed funding has Proxima raised?

As of Jan 13, 2026, Proxima has disclosed funding of $80M (USD). Undisclosed round amounts are excluded.

How many employees does Proxima have?

Proxima has 11-50 employees as of Apr 15, 2026.

Classification

Industry: Biotechnology
Drug Discovery
Ownership: Venture-backed
Technology: AI
Machine Learning
Geographic Exposure: North America

Model: Drug Discovery Platform
Revenue: B2B
Customer: Pharmaceutical Companies
Main Product: AI Drug Discovery

Tags: Biotech

Also Known As: Proxima Bio, Inc.

Headquarters: 116 E 16th Street
Floor 12
New York, NY, 10003
US

SEC CIK: 0002104665
EIN: 84-3434923